Zydus Lifesciences Limited
ZYDUSLIFE
Classificação em ações
#1750
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Preço da ação
$12.30
Valor de mercado
$12.27B
Variação (1 dia)
0.06%
Variação (1 ano)
8.33%
País
IN
Negociar Zydus Lifesciences Limited (ZYDUSLIFE)
Categoria
Healthcare
Rácio P/S de Zydus Lifesciences Limited (ZYDUSLIFE)
Rácio P/S em October 2026 TTM: 3.94
De acordo com os relatórios financeiros mais recentes e o preço das ações da Zydus Lifesciences Limited, o rácio P/S atual (TTM) é 3.94. No final de 2024, o rácio P/S era 5.18.
Histórico do rácio P/S da Zydus Lifesciences Limited de 2004 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 3.94 | 3.72% |
| 2025 | 3.80 | -26.59% |
| 2024 | 5.18 | 74.98% |
| 2023 | 2.96 | 22.93% |
| 2022 | 2.41 | -23.84% |
| 2021 | 3.16 | 59.50% |
| 2020 | 1.98 | -28.35% |
| 2019 | 2.76 | -18.65% |
| 2018 | 3.40 | -29.18% |
| 2017 | 4.80 | 45.51% |
| 2016 | 3.30 | -20.00% |
| 2015 | 4.12 | 41.90% |
| 2014 | 2.91 | 22.44% |
| 2013 | 2.37 | -22.24% |
| 2012 | 3.05 | -15.77% |
| 2011 | 3.62 | 18.07% |
| 2010 | 3.07 | 136.85% |
| 2009 | 1.30 | -0.58% |
| 2008 | 1.30 | -40.68% |
| 2007 | 2.20 | -59.66% |
| 2006 | 5.45 | 25.08% |
| 2005 | 4.35 | -50.77% |
| 2004 | 8.84 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 79.07% |
IN
|
